Accusing critics of “no facts” and “misinformation” while offering unsubstantiated claims of greed, billionaires, manipulation, and message-board influence is not a factual rebuttal. It also doesn’t actually counter the point being made. Motive attribution doesn’t substitute for evidence or causal analysis, and it doesn’t explain regulatory timelines, filings, or execution.
Even if one assumes share-price manipulation occurred, that has no bearing on MHRA review standards and does not explain the absence or delay of an FDA application. Market activity doesn’t determine whether an application is filed or approved; regulatory readiness and company decisions do.
Market Data 
Markets 
AI
